Karen has over 20 years of pharmaceutical marketing experience at global and country levels across various therapeutic areas, including Cardiovascular, Respiratory, Endocrinology, Haematology, Psychiatry, Pain Management and Diabetes. She has worked with leading companies such as Pfizer, Advanz Pharma, Cipla, Bayer, and various global alliances.
Her expertise includes developing global brand strategies, driving market-leading launches, and managing product life cycles from pre-launch to loss of exclusivity, all aimed at optimising the customer and patient experience. Known for her innovative thinking, Karen is passionate about gaining customer insights to enhance brand plans and deliver a competitive edge. Balancing short- and long-term brand goals, Karen uses strong analytical skills to address key strategic challenges.
Karen is adept at managing complex internal and external stakeholder landscapes across different organisational cultures and between global and local teams to deliver strong engagement, alignment, and implementation. She has a proven track record of driving growth for several market-leading brands. She led the global launch of Mytolac, a rare disease brand, worked across the BMS-Pfizer alliance launching Eliquis, which achieved market leadership within 3 years, and life cycle managed Lyrica, Toviaz and Dynastat to deliver YOY double-digit revenue growth through patent expiry.
A strategic thinker, Karen describes herself as passionate, innovative, collaborative, and solution-focused.
